The July 10, 2017, article by Hyman et al entitled “AKT Inhibition in Solid Tumors With AKT1 Mutations” (J Clin Oncol 35:2251-2259, 2017) was published with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.
Dr. Baselga’s COIs were given as:
José Baselga
Leadership: Infinity Pharmaceuticals, Varian, Tango
Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Varian Medical Systems
Consulting or Advisory Role: Eli Lilly, Novartis, GRAIL
They should have read as:
José Baselga
Leadership: Infinity Pharmaceuticals, Varian, GRAIL
Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Varian Medical Systems, Tango, Aura Biomedical, Apogen, Northern Biologics
Honoraria: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Northern Biologics
Consulting or Advisory Role: Eli Lilly, Novartis
Research Funding: Roche/Genentech
Patents, Royalties, Other Intellectual Property: Combination Therapy using PDK1 and PI3K inhibitors. Pending. MSK owned, listed as investigator. Use of phosphoinositide 3- kinase inhibitors for treatment of vascular malformations. Licensed. MSK owned, listed as investigator.
Travel, Accommodations, Expenses: Roche/Genentech, Daiichi
This has been corrected as of January 11, 2019. The author apologizes for the errors.